Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells $424,313.10 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) SVP Adam Veness sold 3,833 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $110.70, for a total transaction of $424,313.10. Following the completion of the sale, the senior vice president directly owned 3,833 shares in the company, valued at approximately $424,313.10. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Dianthus Therapeutics Stock Down 2.5%

Shares of NASDAQ:DNTH opened at $109.60 on Friday. The firm has a market cap of $5.99 billion, a P/E ratio of -26.41 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 12-month low of $19.84 and a 12-month high of $114.55. The business has a fifty day simple moving average of $96.76 and a 200 day simple moving average of $82.61.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, equities research analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on DNTH. HC Wainwright upped their target price on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Wedbush increased their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $124.27.

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after purchasing an additional 618 shares in the last quarter. American Century Companies Inc. boosted its holdings in shares of Dianthus Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock worth $1,009,000 after buying an additional 6,323 shares in the last quarter. Invesco Ltd. grew its position in shares of Dianthus Therapeutics by 31.1% during the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock worth $390,000 after buying an additional 4,962 shares during the period. Alliancebernstein L.P. grew its position in shares of Dianthus Therapeutics by 14.5% during the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after buying an additional 149,200 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics in the 2nd quarter valued at $27,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.